How do you treat anti-NMDA receptor encephalitis?

Luca Bartolini, MD

Anti–NMDA receptor (anti-NMDAR) encephalitis was first described in 2007 and is now recognized as one of the most common forms of encephalitis. Anti-NMDAR encephalitis is considered a multistage disease, characterized by nonspecific prodromal flu-like symptoms, followed by acute onset of psychiatric manifestations such as psychosis, delusions, hallucinations, anxiety, insomnia, repetitive behaviors, echolalia, and mutism. Patients at this stage generally present to either neurology or psychiatry services. This phase is usually followed by a change in level of alertness with periods of extreme agitation and catatonia along with the appearance of the classic orofacial and lingual dyskinesias or other movement disorders and pronounced autonomic instability. The combination of autonomic storms and coma often leads to a prolonged intensive care unit (ICU) admission. Patients—children in particular—can also develop focal or generalized seizures. Anti-NMDAR encephalitis can be associated with a tumor, especially ovarian teratomas in female patients older than 12 years. Brain MRI is normal in up to 67% of patients, whereas EEG is abnormal in 90% of patients. EEG findings are nonspecific and can include slowing, disorganization of the background, and electrographic seizures. The diagnosis is confirmed by the presence of NMDAR antibodies in the CSF.

Current evidence on treatment

Treatment protocols consist of supportive measures, immunotherapy, and tumor removal, when present. Generally, first-line immunotherapies for this condition consist of high-dose steroids, IV immunoglobulin (IVIg), and plasma exchange (PE). Different institutions have utilized these treatments alone, in combination, or sequentially; as of yet, no data have confirmed the superiority of one approach over the others. Rituximab and cyclophosphamide are usually considered second-line treatments, and reserved for those patients who fail the first line.

A large observational study that examined 577 patients reported the following: 94% of patients underwent first-line therapy or tumor removal and half of them improved significantly after 4 weeks. A total of 57% of the patients who did not improve received second-line treatments.
agents. A total of 78% of treated patients achieved a modified Rankin Scale score ≤2 by 24 months compared with only 55% of those who did not receive second-line therapy (odds ratio 2.69, 95% confidence interval 1.24–5.80). Overall, 81% of patients had a good outcome at 24 months and second-line immunotherapy also decreased the risk of relapses. Other factors associated with good outcome included tumor removal (when present), no need for admission to the ICU, and shorter interval between symptom onset and treatment. A total of 45 patients had one or multiple relapses (a 12% risk within 2 years).

Other small series have analyzed the outcome of both pediatric and adult patients with anti-NMDAR encephalitis and concluded that early therapy is important for improved clinical outcome.4–6

To date, there has been no prospective open-label treatment trial to evaluate the efficacy of these treatments and all existing evidence is graded as Class IV (according to the American Academy of Neurology Classification of Evidence Matrices for therapeutic, causation, and prognostic questions).7

Expert opinion: Josep Dalmau, MD, PhD

At present, there is no standardized protocol. We have used combined IVIg 0.4 g/kg/d for 5 days and methylprednisolone 1 g/d for 5 days as first-line treatment, with no steroid taper afterwards. There are no data to support that PE is superior to IVIg. From an immunological perspective, the antibodies are synthesized both systemically and inside the brain so PE can remove them systemically but cannot alter the autoimmune process that is going on inside the brain. This is why up to 14% of patients do not have serum antibodies but do have positive CSF.8 Also, it can be very challenging to do it in patients with autonomic instability and extreme agitation. The response to first-line treatment is usually evaluated clinically after 10–15 days (titers help with the diagnosis but not with the efficacy of treatment). More than half of the patients fail to respond and they will benefit from second-line immunotherapy, which usually consists of rituximab (that eliminates the B-cell lineage and therefore prevents the formation of plasma cells), given for example at a dose of 375 mg/m² every week for 4 weeks and often times combined with monthly cycles of cyclophosphamide 750 mg/m² for 4–6 months (an alkylating agent that interferes with DNA replication and eliminates T regulatory cells—Ed.), especially in adults. Now I believe we are moving more toward a comprehensive immunotherapy that consists of giving rituximab, IVIg or PE, and methylprednisolone up front all at the same time. In Hospital Clinic at the University of Barcelona, we include as part of this comprehensive immunotherapy rituximab and both PE and IVIg. In this protocol, 6 PE are given over 10 days, with replacement of the protein losses with albumin, and followed by IVIg. At this time, it is unclear whether the combination of PE and IVIg is better than one of them alone, but I am of the opinion that early aggressive treatment is extremely important to alter the natural course of the disease, which can be lethal, and to prevent relapses. If a patient has a relapse, we usually consider repeating the same treatment that had helped initially or giving a second-line agent if it was not given previously. We currently do not use mycophenolate and azathioprine. In fact, there are no studies to show that these drugs are effective in the acute stage or are useful to prevent relapses. We definitely need multicenter prospective studies to evaluate the efficacy of all these immunotherapies.
Preliminary poll results (December 15, 2015; 9 AM EST)
The preliminary results from the first 172 responders 2 weeks after the poll launched show that almost 50% (n = 80) utilize IVIg and high-dose steroids as first-line treatment. A small but growing number of readers (n = 16) seems to agree with Dr. Dalmau’s approach and utilize the aforementioned comprehensive immunotherapy. The majority (n = 11) in this subgroup resides outside of the United States. It will be interesting to see if there is indeed a different comfort zone in regard to immunotherapy in other countries or if these numbers will change over time with more responses. So far, there is no surprise in terms of second-line treatment, which is usually considered 1 (38%) or 2 weeks (39%) after first-line treatment and is dominated by rituximab alone (61%), even with 80% of responders in this subgroup whose practice is adult-based.

Thirty percent (n = 48) of those who have participated thus far are residents or fellows. It is encouraging to see how trainees are supporting this new editorial journey. Their opinion is invaluable, and sometimes may reflect in a single answer what an entire university-based group does on average.

CONCLUSION
It is clear that there is no single right answer to the question “How do you treat anti-NMDA receptor encephalitis?” Decisions are currently based on level IV evidence. Knowing that several patients with anti-NMDAR encephalitis improve after first-line treatment, with an overall low rate of relapse, and knowing that all the immunotherapeutic options have side effects, would you treat those patients using the proposed comprehensive immunotherapy approach or would you rather use a stepwise approach? The debate is still open.

We look forward to this ongoing participation from neurology enthusiasts at all levels of training and to generating more discussions and studies based on a genuine Socratic principle: “I know that I know nothing.”

Josep Dalmau, MD, PhD, is currently Research Professor at the Catalan Institution for Research and Advanced Studies (ICREA) in IDIBAPS/Hospital Clinic, Associate Professor at the University of Barcelona, Adjunct Professor of Neurology at the University of Pennsylvania, and Guest Researcher at the National Institute of Health (NIH). Dr. Dalmau’s research is focused on autoimmune and paraneoplastic neurologic disorders. His recent work has revealed a new category of disorders mediated by antibodies to neuronal cell surface and CNS synaptic proteins. Dr. Dalmau is editor of Neurology: Neuroimmunology & Neuroinflammation, associate editor of Neurology, and serves on the editorial board of the Journal of Neurology. He has served or chaired many scientific committees, including the Basic Science and Neuro-oncology Subcommittees of the American Academy of Neurology and the Annual Special Interest Group in Autoimmune Neurology at the annual meeting of the American Neurological Association. His research is funded by the NIH and the Spanish Health Institute. Dr. Dalmau has contributed to numerous textbooks and has published in leading journals including the New England Journal of Medicine, Journal of Clinical Oncology, Neurology, Lancet Neurology, Brain Pathology, Annals of Neurology, Brain, and Cell.

REFERENCES


AUTHOR CONTRIBUTIONS
Dr. Luca Bartolini designed and drafted the article and interviewed the expert.

STUDY FUNDING
No targeted funding reported.

DISCLOSURES
L. Bartolini serves as the Practice Current Section Editor for Neurology: Clinical Practice.
Practice Current: How do you treat anti-NMDA receptor encephalitis?
Luca Bartolini

DOI 10.1212/CPJ.0000000000000219

This information is current as of January 29, 2016